Largest Published Real-World Wound Imaging Study Reports MolecuLight® led to Wound Treatment Plan Changes in up to 53% Cases

May 23, 2023 -Results from 211 Facilities Show MolecuLight Imaging is a Valuable Tool in Improving Bacterial Infection Management

TORONTO, ON – (May 23, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated, pathogenic bacterial loads in and around wounds, announced the publication of their latest publication,

… Read More

MolecuLight Featured in Unprecedented 24 Presentations and Posters at European Wound Management Association (EWMA) 2023 Annual Conference

May 3, 2023 -Wide-Spread Clinical Evidence using the MolecuLight Imaging Platform Revealsits Significant Global Adoption and Proven Utility in Wound Care

Toronto, CANADA and Milan, ITALY – (May 3, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that detects and locates elevated bacterial loads in wounds, announces that its MolecuLight wound

… Read More

MolecuLight Partners with WoundZoom to Deliver Cloud-Based Wound Management Solution Integrated with its Point-of-Care Bacterial Imaging

April 27, 2023 -Wound Care Clinicians Can Now Manage All Wound Care Documentation, MolecuLight Images and Measurements via a Robust, Scalable Cloud Platform

National Harbor, MD – April 27, 2023 – MolecuLight Corp., the leader in point-of-care fluorescence imaging that detects and locates elevated bacterial loads in wounds, announced today that the company has

… Read More

New Publication Reveals MolecuLight Imaging Significantly Improved Detection of Bacterial Burden Across Patients of All Skin Tones

April 25, 2023 -Findings show that MolecuLight is an Objective and Equitable Diagnostic Technology Positioned to Help Level Racial Disparity in Wound Care Outcomes

TORONTO, ON – (April 25, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced the publication

… Read More

MolecuLight Successfully Completes SOC 2® Type I Audit and Accreditation

April 19, 2023 -Successful completion of recent audit demonstrates MolecuLight’s commitment to data security

TORONTO, ON – (April 19, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced that it is in compliance with SOC 2® Type I, having successfully

… Read More

Chronic Inhibitory Bacterial Load (CIBL): New Clinical Terminology for Elevated Levels of Bacteria in Wounds that Preclude Healing

February 14, 2023 -Findings from a New Clinical Study Using MolecuLight Imaging of Diabetic Foot Ulcers Prompts New Diagnostic Terminology Enabling Proactive Infection Management

TORONTO, ON – (February 14, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced the publication

… Read More

MolecuLight Featured in Vizient Tech Watch as Key Technology for Visualizing Bacterial Burden and Helping to Reduce Surgical Site Infections

December 6, 2022 -Article is a Follow-On to MolecuLight’s Receipt an Innovative Technology Contract from Vizient Last Year

PITTSBURGH, PA – (December 6, 2022) MolecuLight Corp., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, is featured in Vizient’s newly released Tech Watch publication as a

… Read More

MolecuLight Featured in 10 Presentations and Posters at the AAWC 2022 Annual Conference

November 10, 2022 -Unprecedented Body of New Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates Improved Clinical Decision-Making and Patient Outcomes

Toronto, CANADA and Salt Lake City, UTAH – (November 10, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that

… Read More

Previous